GRFS vs PTGX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GRFS presents a classic 'value trap' profile: strong deterministic health (Piotroski F-Score 7/9) and deep valuation discounts (Price < Graham Number < Intrinsic Value), yet it suffers from severe market rejection. While the stock trades at a significant discount to its Graham Number of $11.36 and Intrinsic Value of $18.88, this is offset by a 0/100 technical trend and a dismal earnings track record with 0 beats in the last 4 quarters. The disconnect between strong operational health scores and poor price performance suggests systemic risks or lack of catalyst for a reversal.
PTGX exhibits a strong deterministic health profile with a Piotroski F-Score of 7/9 and a fortress-like balance sheet (Current Ratio 12.71, Debt/Equity 0.02). However, the company is in a speculative pre-commercial phase, evidenced by a staggering Price/Sales ratio of 146.96 and negative profit margins. While analysts maintain a 'strong_buy' based on the late-stage pipeline (Icotyde and Rusfertide), significant insider selling by the CEO and CFO creates a divergence between institutional optimism and internal sentiment.
Compare Another Pair
Related Comparisons
GRFS vs PTGX: Head-to-Head Comparison
This page compares Grifols, S.A. (GRFS) and Protagonist Therapeutics, Inc. (PTGX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.